UTHR ▲ +0.1% - United Therapeutics Corporation $UTHR United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis United Therapeutics rose 0.1% after the FDA accepted a supplemental new drug application for a nebulized formulation of its Tyvaso treatment for idiopathic pulmonary fibrosis. The acceptance moves the company closer to potentially expanding Tyvaso's market reach within pulmonary disease treatment, though the modest gain suggests investors are adopting a measured stance ahead of the regulatory review process. 02-SEP-2026 07:00 AM ET